Cello Health PLC Capital Markets Event (6814V)

TIDMCLL

RNS Number : 6814V

Cello Health PLC

10 April 2019

10 April 2019

Cello Health plc

("Cello" or the "Group")

Capital Markets Event

Cello Health plc (AIM: CLL), the healthcare-led advisory group, is this afternoon hosting a capital markets event in London for analysts and institutional investors. The event will focus on the Group's Cello Health division and its strategic growth opportunities in the pharmaceutical and biotechnology industries worldwide.

The event will begin at 2.30pm at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For further details please contact Buchanan on 020 7466 5000 or email [e-mail].

A copy of the presentations accompanying the event will be made available later today at the Group's website: https://cellohealthplc.com.

No new material information will be disclosed during the event.

Enquiries:

 
  Cello Health plc                             020 7812 8460 
  Mark Scott, Chief Executive 
  Mark Bentley, Group Finance Director 
 
  Cenkos Securities (Nominated adviser and 
   broker)                                     020 7397 8900 
  Mark Connelly 
  Harry Hargreaves 
 
  Buchanan                                     020 7466 5000 
  Mark Court 
  Jamie Hooper 
  Sophie Wills 
 

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCDMGGDVLRGLZM

(END) Dow Jones Newswires

April 10, 2019 02:00 ET (06:00 GMT)